Pure Global

Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) - Trial NCT03321890

Access comprehensive clinical trial information for NCT03321890 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sun Yat-sen University and is currently status unknown. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 102 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT03321890
Phase 2
drug
Trial Details
ClinicalTrials.gov • NCT03321890
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Multicenter, Single-arm, Open II Phase Clinical Trial Evaluating the Efficacy of Chidamide Combined With Prednisone, Cyclophosphamide, Etoposide, and Methotrexate (PECM) in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Study Focus

Chidamide

Interventional

drug

Sponsor & Location

Sun Yat-sen University

Guangzhou, China

Timeline & Enrollment

Phase 2

Mar 07, 2017

Dec 31, 2020

102 participants

Primary Outcome

Objective response rate

Summary

To observe the efficacy and safety of Chidamide combined with prednisone, cyclophosphamide,
 etoposide and methotrexate in relapsed or refractory PTCL.

ICD-10 Classifications

Peripheral T-cell lymphoma, not elsewhere classified
Cutaneous T-cell lymphoma, unspecified
Mature T/NK-cell lymphomas
Angioimmunoblastic T-cell lymphoma
Other mature T/NK-cell lymphomas

Data Source

ClinicalTrials.gov

NCT03321890

Non-Device Trial